PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY INDICATION • Market segmentation by indication • Comparison by indication • Sickle cell anemia - Market size and forecast 2018-2023 • Sickle beta thalassemia - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by indication PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ADDMEDICA • Bristol-Myers Squibb • Emmaus Medical • Novartis • Pfizer PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Indication - Market share 2018-2023 (%) Exhibit 18: Comparison by indication Exhibit 19: Sickle cell anemia - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Sickle cell anemia - Year-over-year growth 2019-2023 (%) Exhibit 21: Sickle beta thalassemia - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Sickle beta thalassemia - Year-over-year growth 2019-2023 (%) Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Others - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by indication Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Impact of drivers and challenges Exhibit 40: Gene therapy pipeline for sickle cell Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: ADDMEDICA - Vendor overview Exhibit 47: ADDMEDICA - Business segments Exhibit 48: ADDMEDICA - Organizational developments Exhibit 49: ADDMEDICA - Key offerings Exhibit 50: ADDMEDICA - Key customers Exhibit 51: Bristol-Myers Squibb - Vendor overview Exhibit 52: Bristol-Myers Squibb - Business segments Exhibit 53: Bristol-Myers Squibb - Organizational developments Exhibit 54: Bristol-Myers Squibb - Geographic focus Exhibit 55: Bristol-Myers Squibb - Key offerings Exhibit 56: Bristol-Myers Squibb - Key customers Exhibit 57: Emmaus Medical - Vendor overview Exhibit 58: Emmaus Medical - Business segments Exhibit 59: Emmaus Medical - Organizational developments Exhibit 60: Emmaus Medical - Geographic focus Exhibit 61: Emmaus Medical - Key offerings Exhibit 62: Emmaus Medical - Key customers Exhibit 63: Novartis - Vendor overview Exhibit 64: Novartis - Business segments Exhibit 65: Novartis - Organizational developments Exhibit 66: Novartis - Geographic focus Exhibit 67: Novartis - Segment focus Exhibit 68: Novartis - Key offerings Exhibit 69: Novartis - Key customers Exhibit 70: Pfizer - Vendor overview Exhibit 71: Pfizer - Business segments Exhibit 72: Pfizer - Organizational developments Exhibit 73: Pfizer - Geographic focus Exhibit 74: Pfizer - Segment focus Exhibit 75: Pfizer - Key offerings Exhibit 76: Pfizer - Key customers    

ADDMEDICA Bristol-Myers Squibb Emmaus Medical Novartis and Pfizer